| GTO ID | GTC3746 |
| Trial ID | NCT06243770 |
| Disease | Heart Failure |
| Altered gene | RLN |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA |
| Treatment | mRNA-0184 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Phase 1, Randomized, Open-label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-0184 Administered at 2 Different Infusion Durations in Healthy Participants |
| Year | 2024 |
| Country | Australia |
| Company sponsor | ModernaTX, Inc. |
| Other ID(s) | mRNA-CRTX-001 |
| Vector information | |||
|
|||
| Cohort1: duration 1 on Day 1 | |||||||
|
|||||||
| Cohort2: duration 2 on Day 1 | |||||||
|
|||||||